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1. Introduction 
Diabetic retinopathy (DR) is the leading cause of blindness in working-age individuals. 
There is increasing evidence that established risk factors for DR, including duration of 
diabetes, hyperglycemia, and hypertension, only explain a limited amount of the variance in 
the risk of DR. Furthermore, the underlying pathogenesis of DR remains inadequately 
understood. Diabetes causes metabolic and physiologic abnormalities in the retina, and 
these changes suggest a role for inflammation in the development of DR. These changes 
include up regulation of isoforms of nitric oxide synthase (iNOS), cyclooxygenases (COX)-2, 
intercellular adhesion molecule 1 (ICAM-1), vascular endothelial growth factor (VEGF), 
nuclear factor kappa B (NF-κB), increased production of nitric oxide, prostaglandin E2, 
interleukin (IL)- 1ǃ, and cytokines, as well as increased permeability and leukostasis. 
Using selective pharmacologic inhibitors or genetically modified animals, an increasing 
number of therapeutic approaches have been identified that significantly inhibit 
development of at least the early stages of diabetic retinopathy, especially occlusion and 
degeneration of retinal capillaries. A common feature of a number of these therapies is that 
they inhibit production of inflammatory mediators. The concept that localized inflammatory 
processes play a role in the development of diabetic retinopathy is relatively new, but 
evidence that supports the hypothesis is accumulating rapidly. The focus of this chapter is 
on the inflammatory nature of many of the molecular and cellular processes leading to this 
vascular damage, as well as on the pathologic neovascularization that often accompanies it. 
Finally, clinical findings validating the role of inflammation in DR are described. 
2. An inflammation in the early performance of diabetic retinopathy 
Diabetic retinopathy classically has been regarded as a disease of the retinal microvasculature, 
and the natural history of the disease has been divided into an early, nonproliferative (or 
background) stage, and a later, proliferative stage. It is becoming appreciated also that cells of 
the neuroretina also are affected in diabetes. A number of metabolic or molecular 
abnormalities that are characteristic of inflammation have been detected in retinas of diabetic 
animals or patients, or in retinal cells exposed to elevated concentrations of glucose. 
Histologically, vascular lesions in the early stages of diabetic retinopathy in man and animals 
are characterized by the presence of saccular capillary microaneurysms, pericyte deficient 
capillaries, and obliterated and degenerate capillaries. These degenerate capillaries are not 
perfused, and so increases in their frequency represent reductions in retinal perfusion. 
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Capillary occlusion and degeneration initially occurs in single, isolated capillaries, and 
has no clinical importance when only few capillaries have become nonperfused. As more 
and more capillaries become occluded, however, retinal perfusion likely decreases, at 
least locally. Mechanisms believed to contribute to the degeneration of retinal capillaries 
in diabetes include occlusion of the vascular lumen by white blood cells or platelets, death 
of capillary cells secondary to biochemical abnormalities within the vascular cells 
themselves, or capillary cell death secondary to products generated by other nearby cells 
(such as neurons or glia). All species studied today have been found to show degeneration 
of retinal capillaries as well as death of pericytes and endothelial cells, but 
microaneurysms are not commonly found in rodent models of diabetic retinopathy. 
Inflammation is a nonspecific response to injury that includes a variety of functional and 
molecular mediators, including recruitment and activation of leukocytes. Inflammation 
typically has beneficial effects on an acute basis, but can have undesirable effects if 
persisting chronically. The increased expression of many inflammatory proteins is 
regulated at the level of gene transcription through the activation of proinflammatory 
transcription factors, including NF-κB. These proinflammatory transcription factors are 
activated and play a critical role in amplifying and perpetuating the inflammatory 
process. Transcription factors associated with production of proinflammatory mediators 
include NF-κB, activator protein 1 (AP-1), specificity protein 1 (Sp1), peroxisome 
proliferator-activated receptors (PPARs) and other members of the nuclear receptor 
superfamily. Proinflammatory proteins (including COX-2, interleukin-1, tumor necrosis 
factor alpha) can contribute to cell damage and death in tissues including brain and 
retina, at least in part via activation of NF-κB (Fig.1.). 
2.1 NF-κB 
NF-κB is a widely expressed inducible transcription factor that is an important regulator of 
many genes involved in mammalian inflammatory and immune responses, proliferation 
and apoptosis. Evidence in support of an important role of NF-κB in the pathogenesis of 
early stages of diabetic retinopathy is twofold. First, inhibition of proteins whose expression 
is regulated by NF-κB (such as iNOS and ICAM) inhibit diabetes-induced degeneration of 
retinal capillaries. Second, compounds known to inhibit NF-κB likewise inhibit the 
development of the retinopathy. For example, several different antioxidants which inhibit 
the development of capillary degeneration and pericyte loss in retinas of diabetic rats also 
inhibit the diabetes-induced activation of retinal NF-κB. Likewise, low-intermediate doses of 
salicylates (aspirin, sodium salicylate, and sulfasalazine) which inhibited NF-κB activation 
in retinas of diabetic rats, also inhibited expression of inflammatory mediators like iNOS 
and ICAM-1, and capillary degeneration and pericyte loss in those animals. Aspirin is 
known to inhibit also production of prostaglandins, but salicylate and sulfasalazine have 
much less of this activity, suggesting that the common action of these 3 salicylates to inhibit 
retinopathy in diabetes was not primarily mediated by inhibition of prostaglandins. 
Our experiments showed that Ubiqutin-proteasome system can influence the occurrence 
and development of DR by regulating NF-κB and IκB expression. Application of MG 132, 
ubiqutin-proteasome inhibitor, can inhibit the ubiquitination of IκB degradation, and block 
the activation of NF-κB, which may play an early intervention role in DR. 
www.intechopen.com
 
Inflammation and Diabetic Retinopathy 
 
127 
2.2 iNOS 
iNOS expression is regulated at least in part by NF-κB. Interestingly, experimental 
sympathectomy itself increases gene and protein expression of iNOS in retinas of 
nondiabetic rats, suggesting that loss of sympathetic activity, such as which occurs in 
diabetes, might contribute to the upregulation of this inflammatory protein in the retina. In 
retinas of diabetic animals, increased levels of nitric oxide products (nitrotyrosine, nitrite, 
nitrate) have been reported. Upregulation of iNOS has been found in retinas of experimental 
diabetic rodents and patients in most studies. Diabetes-induced alterations inexpression of 
other isoforms of nitric oxide synthase also have been reported. A possible role of iNOS in 
the pathogenesis of diabetic retinopathy is suggested by the studies of aminoguanidine. 
Aminoguanidine is a relatively selective inhibitor of iNOS, and has been found to inhibit the 
diabetes-induced increase nitric oxide production and iNOS expression in retina. 
Aminoguanidine also has been found to inhibit the development of the microvascular 
lesions of diabetic retinopathy in diabetic dogs, rats, and mice. Nevertheless, 
aminoguanidine also has other effects, so this therapy does not absolutely prove a role of 
iNOS in the pathogenesis of the retinopathy. The role of iNOS in the development of the 
early stages of diabetic retinopathy recently has been investigated directly using mice 
genetically deficient in iNOS. In that study, wildtype diabetic mice developed the expected 
degeneration of retinal capillaries, as well as increase in leukostasis and superoxide 
generation. In contrast, diabetic mice deficient in iNOS did not develop these structural or 
functional abnormalities. eNOS expression also has been reported to be elevated in the 
retinas in the diabetic rats, and it has been suggested that eNOS might play a role in the 
development of diabetes-induced leukostasis and/or retinopathy. This posibility has not 
been experimentally addressed due, in part, to the hypertension that results in the absence 
of eNOS, as well as a lack of specific inhibitors of the enzyme. 
2.3 Cyclooxygenases 
COX-2 expression is regulated at least in part by NF-κB. In retinas of diabetic animals, 
induction of COX-2 as well as increased production of prostaglandins has been reported. 
Researchers have shown that PGE2 production by retinas from diabetic rats was significantly 
inhibited by celecoxib (a selective COX-2 inhibitor), but not by a COX-1 inhibitor, suggesting 
that COX-2 is primarily responsible for the diabetes-induced increase in retinal production of 
PGE2 in diabetic rats. Inhibition of COX-2 has been reported to inhibit the diabetes-induced 
upregulation of retinal prostaglandins and VEGF, the increase in retinal vessel permeability 
and leukostasis, and the death of retinal endothelial cells cultured in diabetic-like 
concentrations of glucose. The COX-2 inhibitor, Meloxicam, also reduced eNOS levels, 
inhibited NF-κB activation in the diabetic retina, and modestly, but significantly, reduced 
TNFǂ levels in the retina. Its effect on histologic lesions of diabetic retinopathy was not 
studied. Less selective COX inhibitors have inhibited the development of the retinopathy in 
diabetic dogs and rodents, as well as the increase in vascular permeability in diabetic rodents. 
Nepafenac is an inhibitor of cyclooxygenases that can be applied in eye drops. It was found to 
inhibit diabetes-induced prostaglandin production and leukocyte adhesion in retinal vessels 
of diabetic rats, and the diabetes-induced increase in the number of TUNEL-positive capillary 
cells, acellular capillaries, and pericyte ghosts in the retina. 
Micro RNAs (miRNAs) are a class of highly conserved, small non-coding RNAs that 
powerfully regulate gene expression at the posttranscriptional level. A growing number of 
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reports have established a link between miRNAs and DR in recent years. Kovacs B et al. 
proposed upregulation of NF-κB-, VEFG-, and p53- responsive miRNAs constituted key 
miRNA signatures, reflecting ongoing pathologic changes of early DR. But the exact roles of 
miRNAs in DR are still unknown. Our teams are still devoting the study of differentially 
expressed miRNA of human retinal capillary endothelial cells in high glucose environment 
by miRNA gene chip.(Table 1,2) 
 
Table 1. The up-regulated miRNA炷Fold change>2) A: Normal control group  B: High 
glucose group 
Table 2. The down-regulated miRNAs( Fold change<0.5) A: Normal control group  B: High 
glucose group 
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3. Leukocyte activation and endothelial cell injury 
Attraction and adhesion of leukocytes to the vascular wall are important components of 
inflammatory processes. This leukostasis has been found to be significantly increased in 
retinas of diabetic animals, and might contribute to the capillary nonperfusion in diabetic 
retinopathy. Leukocyte stiffness has been reported to be increased in diabetes (decreased 
filterability) and to contribute to the development of capillary nonperfusion in retinal 
vessels. A second line of evidence shows that abnormal leukocyte adherence to retinal 
vessels in diabetes occurs via adhesion molecules. 
 
Fig. 1.Role of aldose reductase in mediation of inflammatory signals. Cytokines, growth 
factors (GF), and lipopolysaccharide (LPS) cause oxidative stress via generation of ROS 
which forms toxic lipid aldehydes such as HNE by lipid peroxidation. HNE being highly 
electrophilic conjugates with cellular glutathione (GSH) spontaneously or catalyzed by GST 
to form GS-HNE. The reduced products of GS-aldehydes, GS-DHN, transduce 
inflammatory signaling via cascade of protein kinases leading to activation of NF-κB. 
Activation of NF-κB transcribes genes responsible for various inflammatory 
pathologies.炷Reproduced from Int J Biochem Cell Biol. 2010 January ; 42(1): 17–20. 
doi:10.1016/j.biocel.2009.09.009.炸 
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Diabetes increases expression of ICAM-1 in retinas of animals and humans and interaction 
of this adhesion molecule on retinal endothelia with the CD18 adhesion molecule on 
monocytes and neutrophils contributes to the diabetes-induced increase in leukostasis 
within retinal vessels. Leukostasis has been postulated to be a factor in death of retinal 
endothelial cells in diabetes. Using in situ perfusion methods, evidence consistent with 
capillary occlusion secondary to leukostasis has been observed in occasional retinal vessels, 
but it is unclear whether this occurred in vivo or was an artifact caused by the perfusion in 
vitro. Retinas from diabetic mice lacking ICAM-1 and CD18 are protected from the 
development of diabetes-induced increase in leukostasis, vascular permeability, and 
degeneration of retinal capillaries, showing these proteins to be important in the 
development of early stages of diabetic retinopathy. Whether their role in the development 
of the retinal disease results from capillary occlusion or some other mechanism, however, 
has not been explored. 
In experimental studies employing rodent models of diabetes, diabetic retinal vascular 
leakage, capillary nonperfusion, and endothelial cell damage are temporally and spatially 
correlated with a low-level leukocyte influx and persistent retinal leukostasis. This 
leukostasis is mediated by retinal upregulation of ICAM-1, together with an increased 
expression of its cognate integrin ligands on neutrophils. Subsequently, endothelial cell 
injury and death result from Fas/FasL-mediated apoptosis. 
In response to this injury, the endothelium maintains a sustained high rate of cell division, 
which is believed to result in exhaustion of its regenerative capacity. This stress is further 
exacerbated by a diabetes-induced defect in the ability of endothelial precursor cells to 
repair the damaged vasculature. While the vascular damage is primarily a function of 
infiltrating leukocytes, DR is also associated with ischemic neovascularization, a process 
that is amplified by the influx of macrophages. 
4. Causes of inflammation 
4.1 Vascular Endothelial Growth Factor (VEGF) 
VEGF is a proinflammatory molecule that plays a well-recognized role in neovascularization 
and in increased permeability. VEGF expression is regulated largely by hypoxia, but it also 
accumulates in the retina early in diabetes, before any retinal hypoxia is yet apparent. It is 
produced by multiple cell types in the retina in diabetes, including ganglion cells, Müller 
cells, and pericytes. Repeated injections of high concentrations of VEGF in the eyes of non-
diabetic monkeys result in retinal changes which in some ways resemble those in the early 
stages of diabetic retinopathy, including vascular tortuosity and microaneurysms. 
4.2 Tumor Necrosis Factor-α (TNF-α) 
The levels of several proinflammatory cytokines including IL-1ǃ, TNF-ǂ, IL-6, and IL-8 are 
increased in the vitreous of patients with proliferative diabetic retinopathy and in retinas 
from diabetic rodents. Inflammation is one of the processes implicated in the apoptosis of 
retinal cells , and TNF-ǂ is considered as an important mediator of apoptosis of retinal 
endothelial cells in diabetes. 
Evidence supporting a role for TNF-ǂ in DR comes from studies demonstrating  elevations 
of TNF-ǂ in ocular fibrovascular membranes, platelets, and plasma or serum of patients 
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with DR. Vitreous elevations in TNF-ǂ in patients with proliferative DR were reported in 
one study, although another study found no difference in the vitreous levels of TNF-ǂ 
between those with proliferative DR and those with noninflammatory retinopathies. The 
susceptibility to diabetic retinopathy has been associated with TNF-ǂ gene polymorphism 
and expression of HLA-DR3 and HLA-DR4 phenotypes. In addition, TNF-ǂ is found in the 
extracellular matrix, endothelium, and vessel walls of fibrovascular tissue of eyes with 
proliferative diabetic retinopathy. 
Eternacept is a soluble TNF-ǂ receptor that acts as competitive inhibitor to block effects of 
TNF-ǂ binding to cells. Eternacept reduced leukocyte adherence in retinal blood vessels of 
diabetic rats for 1 week compared to control. Eternacept did not reduce retinal VEGF levels, 
but it inhibited blood-retinal barrier breakdown and NF-κB activation in the diabetic retina.  
4.3 Inter-cellular Adhesion Molecule 1 (ICAM-1) 
White blood cells bind to ICAM-1 on the surface of endothelial cells as a component of a 
multistep process leading to adherence of the white blood cell to the endothelial wall. 
ICAM-1 is a peptide known to mediate leukocyte adhesion and transmigration. ICAM-1 
may be operative in the stasis observed in diabetic retinopathy, because ICAM-1 
immunoreactivity is increased in the diabetic retinal vasculature of humans. 
ICAM-1 is upregulated by several stimuli, including VEGF, PARP activation, oxidative 
stress, and dylipidemia, at least in part by NF-κB. 
4.4 Endothelin-1(ET-1) 
ET-1 is one of the strongest vasoconstrictive factors. The DAG/PKC pathway determines 
blood flow dysregulation by decreasing endothelial NOS activity and/or increasing the 
synthesis of ET-1. Observations indicate that the participation of endothelin in coagulation 
disorders is also essential for the development of proliferative diabetic retinopathy (PDR). 
Some studies point out the fact that thrombosis in the rat microcirculation and a DIC-like 
process in the rabbit circulation develop under the influence of ET-1. An important element 
in the development of this disturbance is the documented mitogen-activated protein (MAPK 
kinase)-dependent ET-1 production. Another study has found that the molecular function of 
ET-1 and PKC is predicted. According to this study, different pathways can be derived from 
ET-1 and PKC; however, ET-1–PKC produces the same pathway as PKC. This could mean that 
the interaction between ET-1 and PKC results in increased activity of the PKC pathway but 
does not generate any new pathway.  
4.5 IL-6 
Clinical reports show that IL-6 in the vitreous fluid increases not only in uveitis but also in 
diabetic retinopathy, retinal vein occlusion, and retinal detachment. Research with 
experimental animals has shown that diffusible factors, IL-6 and other proteins in the IL-6 
family, such as leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF), are 
expressed in the retina. Both IL-6 and LIF are found in Müller glial cells, and CNTF is found 
in the retinal ganglion cells and astrocytes around the vessels. These endogenous IL-6 family 
proteins are upregulated during inflammation and function to promote pathogenesis of the 
vascular system. 
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IL-6 family proteins use cytokine-specific receptors to activate a transmembrane receptor, 
gp130, which then recruits Janus kinase (JAK) to activate transcription factor signal 
transducer and activator of transcription 3 (STAT3). STAT3 then regulates various molecules 
at the transcriptional level, including suppressor of cytokine signaling 3 (SOCS3). SOCS3 
acts as a negative feedback modulator of STAT3 by inhibiting JAK and subsequent STAT3 
activation. In the retina, SOCS3 is expressed in the photoreceptor cells, Müller glial cells, and 
retinal ganglion cells, and it inhibits STAT3 activation in these cells. Since STAT3 activation 
induces further STAT3-activating factors, such as the IL-6 family ligands, the balance 
between STAT3 activation and SOCS3 level is one of the key determinants of an 
inflammatory reaction. 
5. Anti-inflammatory and effects of anti-inflammatory drug treatment 
5.1 Glucocorticoid 
Glucocorticoids are well-established anti-inflammatory compounds that may be effective in 
reversing or preventing the progression of macular edema, and are currently under 
investigation as a therapy for diabetic retinopathy. Glucocorticoids are effective at reversing 
VEGF-induced permeability in animal models. In addition to the anti-inflammatory effect of 
glucocorticoids, our laboratory has demonstrated that these steroids also induce the 
synthesis and assembly of tight junctions and the dephosphorylation of occluding 
commensurate with a reduction in endothelial permeability. Recent work revealed the 
presence of a novel enhancer element unlike the canonical glucocorticoid response element, 
in the occludin promoter that controls glucocorticoid responsiveness of this gene 
(manuscript submitted). Future studies may reveal more specific means to control 
expression of the tight junction proteins and barrier properties. 
5.2 Nonsteroidal anti-inflammatory drugs 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed 
classes of medications worldwide. Aspirin and other chemically related compounds, used 
systemically for many decades for their analgesic, antipyretic, and anti-inflammatory 
properties, have more recently been prepared in topical ophthalmic formulations. As such, 
they have proven useful to enhance mydriasis, reduce postoperative inflammation, and 
prevent and treat cystoid macular edema (CME) associated with cataract surgery. In 
addition, they can be used to decrease pain and photophobia after refractive surgery and to 
alleviate itching associated with allergic conjunctivitis.The development of NSAIDs that 
preferentially inhibit COX-2 provides the potential for relieving pain and inflammation 
without the adverse effects of COX-1 blockade, but the advantages of this approach have 
been questioned. Although COX-2 inhibitors may reduce gastro-intestinal toxicity, they 
appear to have equivalent nephrotoxicity to conventional NSAIDs. 
5.3 VEGF drugs for VEGF in the PDR 
Both clinical and preclinical findings have implicated VEGF in the pathophysiology of 
diabetic retinopathy. The VEGF family, which includes VEGF-A, VEGF-B, VEGF-C, VEGF-
D, VEGF-E and placental growth factor, plays an important role in angiogenesis and 
vascular permeability.  
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Three anti-VEGF pharmacologic agents are currently available commercially. Pegaptanib is 
a paginated aptamer that targets the VEGF165 isoform. It has been shown to inhibit VEGF’s 
endothelial mitogen activity and its vascular permeability effects. The US Food and Drug 
Administration (FDA) has approved Macugen for the treatment of neovascular AMD. The 
VEGF Inhibition Study in Ocular Neovascularization (VISION) trial established its safety 
and efficacy in neovascular AMD. Ranibizumab is a recombinant, humanized antibody 
fragment that binds all isoforms of VEGF, whereas bevacizumab (Avastin, Genentech, Inc.) 
is a recombinant, full-length, humanized antibody that also binds all VEGF isoforms. 
Lucentis is currently FDA-approved for neovascular AMD, while Avastin is used on an off-
label basis for a variety of ophthalmic conditions. Large clinical trials of Avastin are 
currently underway for AMD, DME, and vein occlusions, but the safety and efficacy of 
Avastin for intraocular use remains to be demonstrated. 
6. Conclusions 
Acquired visual impairment of DR is the consequence of diabetic blood-retinal barrier 
breakdown. Peroxisome proliferator-activated receptor-gamma excitomotor (PPAR-Ǆ), 
rosiglitazone, lessened much more of the pericytes, and decreased the number of 
proliferative endothelial cells with the lower permeability value of the blood-retinal barrier 
in our DM model rats research, induced by streptozotocin (STZ).  
Diabetic retinopathy is a common microvascular complication in the eyes of diabetic 
individuals. Besides its serious threat to vision, the presence of retinopathy also signifies an 
excess risk of morbidity and mortality attributable to systemic micro and macrovascular 
disease. Numerous defects that develop in retinas as a result of diabetes are consistent with 
diabetes-induced inflammatory response in that tissue. These inflammatory changes 
apparently are important in the pathogenesis of diabetic retinopathy, since inhibition of this 
inflammatory cascade at any of multiple steps can inhibit the early stages of diabetic 
retinopathy in animals. Findings of diabetes induced inflammatory changes, generally, in 
the human eye also, are consistent with the postulate that inflammatory processes contribute 
to the development of diabetic retinopathy. The evidence in diabetic animals is sufficient to 
warrant further investigations of the role of inflammation in the development of diabetic 
retinopathy in patients. 
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